Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBIS-II DCIS: Anastrozole vs Tamoxifen
NCT00072462Phase 3Completed
- Sponsor
- Queen Mary University of London
- Start
- Sep 2003
- Primary completion
- Dec 2015
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of anastrozole in ductal carcinoma in situ (DCIS) (2 arms), sponsored by Queen Mary University of London. Primary endpoint: Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours at 11.6 years. Started Sep 2003; status: completed.
02
Drugs
anastrozole
03
Conditions
ductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NCT00072462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072462.